VYNE Therapeutics Inc. · NASDAQ:VYNE
VYNE Therapeutics — Investor Presentation (May 2023)
60 slides from VYNE Therapeutics's investor presentation, May 15, 2023
Slide 1: Investor Presentation May 2023
INVESTOR PRESENTATION May 2023
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements regarding preclinical and clinical development and timelines for VYNE’s BET inhibitor platform, VYNE’s
Slide 3: Building a Leading Early-Stage Pipeline to Address Unmet Needs in I&I Conditions
Building a Leading Early-Stage Pipeline to Address Unmet Needs in I&I Conditions Multiple paths to potential value creation and catalysts Current Stage Anticipated Milestones Potential Route of Program & Rights Indication(s) Administration Preclinical Phase 1 Phase 2 Phase 3 Recent Updates InhiBETTM
Slide 4: InhiBET™ BET Inhibitor Platform
InhiBET™ BET Inhibitor Platform Bromodomain & Extra-Terminal Domain (BET) Inhibition for Immunology and Inflammatory Diseases 4
Slide 5: BET Proteins Play a Key Role
BET Proteins Play a Key Role in the Regulation of Inflammatory and Oncogenic Genes involved in Several Diseases BRD4 BET proteins “read” acetylated lysines and enable transcription of: N-terminal of histones Pro-inflammatory genes, leading to: • Increased cytokine expression that activate B&T cells
Slide 6: BD1 and BD2 Domains of BET Protein are Recognized as Druggable Targets
BD1 and BD2 Domains of BET Protein are Recognized as Druggable Targets and BET Inhibition Represents a Differentiated Approach to Treating Autoimmune Diseases BRD4 BET Protein • BET proteins are characterized by 2 bromodomains (BD1 and BD2) and 1 extra-terminal domain • BD1 and BD2 enable chromatin
Slide 7: How BET Proteins Fuel the “Vicious Cycle”
How BET Proteins Fuel the “Vicious Cycle” of Pro-Inflammatory Cytokine Production in Autoimmune Diseases Pro-inflammatory cytokines Cytokines bind to 1 cytokine receptors Activation of 2 cytokine NF-κβ kinase complex translation 6 Nuclear 3 translocation BRD4 4 Recruitment of cytokine transcription
Slide 8: BET Inhibitors Block BD1/BD2 Binding
BET Inhibitors Block BD1/BD2 Binding to Acetylated Lysines and Stall Pro-inflammatory Protein Transcription Pro-inflammatory cytokines cytokines 5 1 BET INHIBITOR Binds BD1 and/or BD2 of BRD4 protein making it 4 unable recognize acetylated cytokine histones, recruit translation transcription factors
Slide 9: BD1 and BD2 Play Different Roles in Regulating Gene Expression
BD1 and BD2 Play Different Roles in Regulating Gene Expression Maximizing on-target potency against BD2 and minimizing affinity to BD1 may be the key to optimizing the benefit/risk profile of BET inhibitors for autoimmune diseases BD1 and BD2 role differentiation: Characteristic BD1 BD2 • BD1 regula
Slide 10: VYNE’s Drug Design Strategy
VYNE’s Drug Design Strategy Optimize benefit/risk profile of BET inhibitors to target autoimmune diseases Pan-BD BET Inhibitors BD2-Selective BET Inhibitors Maximize local effect & Improve efficacy and tolerability minimize systemic exposure through BD2-selectivity • Tissue targeted administration r
Slide 11: VYN201
VYN201 Locally administered pan-BET inhibitor
Slide 12: VYN201 – Locally Administered Pan-BD BET Inhibitor
VYN201 – Locally Administered Pan-BD BET Inhibitor Designed as a “soft” drug for tissue targeted administration to maximize local effect and minimize systemic exposure BRD4 BET Protein Potential Target Market: • Vitiligo • Other indications benefiting from local administration and “soft drug” approa
Slide 13: VYN201 Pre-Clinical Efficacy Model Evaluations
VYN201 Pre-Clinical Efficacy Model Evaluations Program designed to investigate the targeted administration of a “soft drug” pan-BD BET inhibitor to maximize local effect and minimize systemic exposure Indication/area Model Administration Route Status Th17 autoimmune diseases IMI-induction mouse mode
Slide 14: Preclinical Proof-of-Concept Data Summary
VYN201: Preclinical Proof-of-Concept Data Summary Potential “pipeline in a product” with broad utility across multiple routes of administration Preclinical models produced consistent reductions in pro-inflammatory & disease-related biomarkers, improvements in disease severity and a demonstrated loca
Slide 15: Vitiligo Preclinical data and Clinical Plan
VYN201: Vitiligo Preclinical data and Clinical Plan
Slide 16: Human Tissue Model of Vitiligo – Demonstrated Inhibition of MMP9
VYN201: Human Tissue Model of Vitiligo – Demonstrated Inhibition of MMP9 Reconstituted human epithelial (RHE) skin cultures were treated with a TNF-α and IFN-ɣ cytokine cocktail to induce a vitiligo phenotype melanocytorrhagy (loss of melanocyte), upregulation of MMP9 and soluble E-cadherin). 24hr p
Slide 17: Human Tissue Model of Vitiligo – Reduction of Soluble E-cadherin
VYN201: Human Tissue Model of Vitiligo – Reduction of Soluble E-cadherin 800 700 600 • Stimulated and vehicle-treated RHE (% untreated unstimulated CTL) 500 488 demonstrated a significant 422 upregulation of soluble E-cadherin, Soluble E-cadherin 359 relative to unstimulated control 400 328 • VYN201
Slide 18: Human Tissue Model of Vitiligo – Effect on Melanocyte Retention
VYN201: Human Tissue Model of Vitiligo – Effect on Melanocyte Retention 700 Relative melanin content in basal layers (% relative to the stimulated 498 600 367 • Stimulated and vehicle-treated RHE 500 demonstrated a significant loss in melanin content, relative to 400 290 unstimulated control control
Slide 19: Human Tissue Model of Vitiligo - Histology
VYN201: Human Tissue Model of Vitiligo - Histology Micrographic images of TRV immuno-stained induced RHE specimens demonstrating the preservation of melanocytes in the basal layer of samples treated with VYN201 1% Melanocyte migration Basal layer Retention of melanocytes at the basal layer Unstimula
Slide 20: Human Tissue Model of Vitiligo – Gene regulation
VYN201: Human Tissue Model of Vitiligo – Gene regulation Preliminary data suggest that VYN201 regulates genes relevant to Vitiligo including impacting WNT pathway which is believed to play a key role in melanocyte regeneration Transcriptome volcano plots of genes relevant to vitiligo (preliminary fi
Slide 21: Phase 1a/b Study Design in Vitiligo
VYN201: Phase 1a/b Study Design in Vitiligo Topline P1b 16-week data results for all 3 cohorts anticipated in Q3 2023 Vitiligo Phase 1a/b design comprising of: Phase 1a Portion (Complete) (N=30: 5 Cohorts with 6 patients each, evaluating 0.025%, 0.1%, 0.5%, 1.0% and 2.0% strengths) A single ascendin
Slide 22: Phase 1a Topline Safety Results
VYN201: Phase 1a Topline Safety Results VYN201 was generally well-tolerated with no clinically relevant TEAEs, meeting the primary objective of the study Summary of safety and tolerability results (N=30 healthy volunteers)*: • No SAEs and no dose adjustments were required • No clinically relevant tr
Slide 23: VYN201 Phase 1a: Clinical Exposure in Healthy Volunteers
VYN201 Phase 1a: Clinical Exposure in Healthy Volunteers No quantifiable VYN201 plasma concentrations above the assay LLOQ supports “soft” drug approach for topical pan-BD BET inhibitor VYN201 Exposure (Phase 1a, Treatment Phase, All Cohorts) 1000.000 VYN201 Plasma Concentration (ng/ml) Free EC50 10
Slide 24: VYN201 Phase 1a: Clinical Hematology in Healthy Volunteers
VYN201 Phase 1a: Clinical Hematology in Healthy Volunteers All hematological parameters, including platelet counts, were within normal ranges, a finding which has not previously been observed with systemically administered pan-BD BET inhibitors Platelet Count (Phase 1a, Treatment Phase, All Cohorts)
Slide 25: Vitiligo Represents an Exciting Opportunity for VYN201
Vitiligo Represents an Exciting Opportunity for VYN201 Positive Phase 1a SAD/MAD study results announced Phase 1b 16-week top-line results for all 3 cohorts anticipated in Q3 2023 Novel Mechanism of Action Significant Unmet Need with Encouraging Data • Vitiligo is a disabling disease impacting • VYN
Slide 26: VYN202: BD2 selective BET inhibitor
VYN202: BD2 selective BET inhibitor
Slide 27: VYN202 – Oral BD2-selective BET inhibitor
VYN202 – Oral BD2-selective BET inhibitor Designed with class-leading selectivity (BD2 vs. BD1), targeting improved efficacy and tolerability as compared to other systemic pan-BD BET inhibitors in development Potential Target Market1: • Immuno-inflammatory indications such Molecular Profile Design a
Slide 28: Potential Value-Creating Milestones To Kick-Off 2023
Potential Value-Creating Milestones To Kick-Off 2023 Building a leading early-stage immuno-inflammatory pipeline VYN201 VYN201 VYN201 Q3 2023: Phase 1b 16- 2023: Selection of 2nd indication FMX114 Positive P1a week TLR in vitiligo (inhaled or injectable) Review Phase 1b/2a results SAD/MAD result
Slide 29: Appendix: VYN201
Appendix: VYN201 %VYNE’ ROOTED IN THERAPEUTICS INNOVATION
Slide 30: Vitiligo Disease / Market Overview
VYN201: Vitiligo Disease / Market Overview
Slide 31: Vitiligo – Disease Overview
Vitiligo – Disease Overview An acquired disorder of dermatologic pigmentation with high impact on self-esteem • Vitiligo is a depigmenting skin disorder Pathophysiology & Clinical Presentation characterized by the loss of melanocytes, which causes typical non-scaly, chalky-white macules • Pathogenes
Slide 32: Vitiligo – Treatment Paradigm
Vitiligo – Treatment Paradigm Only one drug currently approved; Treatment is dominated by non-specific therapeutics Current Treatment Paradigm 1L Corticosteroids Treatment modality is dependent on disease area Vitiligo Key Unmet Need Phototherapy (segmental vs. non-segmental) as well as activity Top
Slide 33: Vitiligo – Epidemiology and Pricing
Vitiligo – Epidemiology and Pricing Large market with high unmet need and lack of approved prescription treatment options U.S. Addressable Patients U.S. Pricing Potential / Analogs Literature suggests • A topical product as an alternative to steroids and/or calcineurin 4 ~60% of patients inhibitors
Slide 34: Th17 Inflammation Model
VYN201: Th17 Inflammation Model
Slide 35: Comparable Efficacy to Superpotent Steroid Clobetasol in Th17 Murine Model
VYN201: Comparable Efficacy to Superpotent Steroid Clobetasol in a TH17-Mediated Murine Inflammation Model; Potential for Greater Tolerability Dorsal depilated BALB-C mice were dosed topically for 14 days with 100mg topical IMI cream (Day 1-7: induction phase, Day 8- 14: treatment phase). N=4 animal
Slide 36: Normal Skin Physiology in TH17-Mediated Murine Inflammation Model
VYN201: Normal Skin Physiology in TH17-Mediated Murine Inflammation Model Suggests VYN201 Well Tolerated (Day 7) VYN201 Vehicle VYN201 0.1% Clobetasol Cream 0.05% • No appreciable improvement in • Substantial resolution of clinical signs • Substantial resolution of clinical signs clinical signs • Sk
Slide 37: VYN201 Significantly Reduced Expression of Key Pro-Inflammatory Proteins
VYN201 Significantly Reduced Expression of Several Key Pro-Inflammatory Proteins Relevant to Th17-mediated Autoimmune Diseases in Human Tissue1 >95% Inhibition seen with assays for IL-36γ & -99.5% LP-10 120 Percent inhibition (IL-17α) 100 Interleukin 36-gamma 80 60 IL36γ is implicated in upregulatin
Slide 38: Fibrotic Tissue & IPF Models
VYN201: Fibrotic Tissue & IPF Models
Slide 39: Demonstrated Anti-Fibrotic Activity without Delay in Healing Time
VYN201: Demonstrated Anti-Fibrotic Activity without Delay in Healing Time in Murine Skin Healing Model Female hairless mice (n=4/group) had two identical 10mm incisions made either side of the flank. Animals were topically dosed 1X daily with 100mg VYN201 vehicle, VYN201 1% or a Hydroalcoholic gel*
Slide 40: Little Evidence of Residual Swelling and Macular Wound Appearance
VYN201: Little Evidence of Residual Swelling and Macular Wound Appearance in Murine Skin Healing Model VYN201 Vehicle VYN201 1% Hydroalcoholic gel • Still evidence of minor swelling • Little evidence of residual swelling • Moderate swelling clearly evident at around incision sites • Wound appears mo
Slide 41: Bleomycin-Induced Mouse Model of Pulmonary Fibrosis
VYN201: Bleomycin-Induced Mouse Model of Pulmonary Fibrosis Marked improvement in oxygen saturation after three doses Marked improvement in oxygen saturation after just 3 doses, reaching 92.4% at Day 21 for the VYN201 1mg/ml group (sham = 95.2% at Day 21) • VYN201 demonstrated a dose-dependent impro
Slide 42: Significant reductions in both lung fibrosis and hydroxyproline
VYN201: Bleomycin-Induced Mouse Model of Pulmonary Fibrosis Significant reductions in both lung fibrosis and hydroxyproline1 10 ✱ ✱ • VYN201 at 0.5mg/ml and Hydroxyproline levels (ug/g) 0.08 1mg/ml demonstrated 8 statistically significant reductions Ashcroft Score 0.06 ✱ in Ashcroft scores (a ✱ 6 ✱
Slide 43: >50% increase in functional lung volume compared to placebo
VYN201: Bleomycin-Induced Mouse Model of Pulmonary Fibrosis >50% increase in functional lung volume compared to placebo ✱ ✱ 800 • Dose dependent improvement in functional lung volume for groups treated with VYN201 600 Volume (mm3) • Correlates with an increase in blood oxygen saturation and reductio
Slide 44: Representative CT images showing loss in functional lung volume
VYN201: Bleomycin-Induced Mouse Model of Pulmonary Fibrosis Representative CT images showing detectible loss in functional lung volume B Loss of functional lung tissue C Improvement of functional lung tissue mass Sham (Untreated/un-stimulated) Bleomycin + Placebo Bleomycin + VYN201 1mg/ml • VYN201 d
Slide 45: VYN201 treatment supported significant lung recovery
VYN201: Bleomycin-Induced Mouse Model of Pulmonary Fibrosis VYN201 treatment supported significant lung recovery by reducing fibrotic tissue deposition compared to placebo treatment Sham Bleomycin + Placebo Bleomycin + VYN201 1 mg/ml B A E F C A B D A: Normal lung parenchyma with open airways B: Con
Slide 46: Arthritis
VYN201: Arthritis eV YNE’
Slide 47: CAIA Mouse Model of Arthritis – Paw Thickness
VYN201: CAIA Mouse Model of Arthritis – Paw Thickness Marked inhibition of paw thickening/swelling Inflammatory arthritis was induced in BALB/C mice using a mixture of four arthritogenic MAbs by IV injection at Day 0 and was further challenged with an LPS IV injection at Day 4 (N=7/treatment group).
Slide 48: CAIA Mouse Model of Arthritis – Arthritis Score
VYN201: CAIA Mouse Model of Arthritis – Arthritis Score Demonstrated dose dependent reduction in disease severity 3.50 VYN201 VYN201 VYN201 Vehicle IA 10mg/kg IA 1mg/kg IA Clear dose-response demonstrated between VYN201 VYN201 Dexamethasone 3.00 0.1mg/kg IA 0.01 mg/kg IA 1mg/kg IP VYN201-treated gro
Slide 49: CAIA Mouse Model of Arthritis – Systemic Impact
VYN201: CAIA Mouse Model of Arthritis – Systemic Impact Demonstrated localized dose-dependent effect 2.00 Paw Thickness VYN201 VYN201 VYN201 VYN201 Vehicle IA 10mg/kg IA 1mg/kg IA 0.1mg/kg IA 1.50 VYN201 Dexamethasone Dexamethasone 0.01 mg/kg IA 1mg/kg IP 1mg/kg IA Δ untreated - treated leg Paw thic
Slide 50: CAIA Mouse Model of Arthritis – Histopathology
VYN201: CAIA Mouse Model of Arthritis – Histopathology Joint histopathology confirmed arthritis clinical scoring & local effect Inflammation marked with asterisk; damage to bone marked with a blue arrow; inflammatory cells and cellular debris in the joint space marked with red arrow; damage to carti
Slide 51: Appendix: FMX114
Appendix: FMX114 Tofacitinib and Fingolimod Topical Gel for AD 51
Slide 52: FMX114: Two Validated Modes of Action
FMX114: Two Validated Modes of Action Designed to address both the source & cause of inflammation in AD Tofacitinib (Janus kinase Inhibitor) Reduces Fingolimod (Sphingosine 1-phosphate receptor inflammation intracellularly by inhibiting cytokine release from modulator) Reduces inflammation by inhibi
Slide 53: FMX114: Targeting a Multi-factorial Solution for a Multi-factorial Disease
FMX114: Targeting A Multi-factorial Solution for a Multi-factorial Disease Comparison to select topical products approved or in development for the treatment of AD: Aryl FMX114 JAK PDE4 hydrocarbon Gluco- Calcineurin Characteristic Target Inhibitors Inhibitors receptor Corticosteroids Inhibitors Pro
Slide 54: FMX114 Phase 1b/2a Proof of Concept Study Design
FMX114 Phase 1b/2a Proof of Concept Study Design Randomized, double-blinded, vehicle-controlled Phase 1b/2a trial with separate open-label active treatment phase evaluating the safety, pharmacokinetics & efficacy of FMX114 gel vs. vehicle gel in the treatment of mild-to-moderate atopic dermatitis FM
Slide 55: FMX114 Phase 1b Safety and Pharmacokinetics
FMX114 Phase 1b Safety and Pharmacokinetics Highlights • Systemic bioavailability of JAK inhibitor (tofacitinib) and S1P receptor modulator (fingolimod) in topical formulation substantially lower compared to oral equivalents • Mean Cmax of tofacitinib 50-fold and 1500-fold lower at Day 1 and 14 of s
Slide 56: FMX114 Phase 2a Efficacy Data
FMX114 Phase 2a Efficacy Data Highlights • Efficacy data for the Phase 2a trial was measured based on the absolute and percent change relative to baseline in the ADSI scoring assessment at week 4: • FMX114 was statistically superior to vehicle up to and including week 3; numerically superior at week
Slide 57: FMX114 Phase 2a Subanalyses
FMX114 Phase 2a Subanalyses Percent Reduction in ADSI Score by Baseline Score Baseline ADSI score of 6 through 91 Baseline ADSI score of 7 through 91 Baseline ADSI score of 8 through 91 (Mean ADSI = 6.6 active; 6.9 vehicle) (Mean ADSI = 7.6 active; 7.9 vehicle) (Mean ADSI = 8.7 active; 8.7 vehicle)
Slide 58: FMX114 Phase 1b/2a Results Summary
FMX114 Phase 1b/2a Results Summary FMX114 drug effect and proof-of-concept established • On target PK and safety profile met • Statistically significant efficacy results at weeks 1, 2 and 3; Primary efficacy endpoint at week 4 not met but numerically superior • Continued effect demonstrated throug
Slide 59: Phase 2b Study Design Applies Key Learnings from Phase 2a
Phase 2b Study Design Applies Key Learnings from Phase 2a: Phase 2a Key Learnings & Rationale Phase 2b • 2-arm double-blind intra-lesional • Eliminate risk of patients using active • Conventional 4-arm double blind design design with patient acting as self- drug on lesions assigned to vehicle (pivot
Slide 60: NASDAQ: VYNE
rd a THERAPEUTICS NASDAQ: VYNE